Kinetics of pertussis immune responses to tetanus-diphtheria- acellular pertussis vaccine in health care personnel: Implications for outbreak control

Clinical Infectious Diseases

Volumn 49, Issue 4, 2009, Pages 584-587

  Kirkland, Kathryn B ^a   Talbot, Elizabeth A ^a   Decker, Michael D ^b,c   Edwards, Kathryn M ^d  

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^b SANOFI PASTEUR   (France)

^c VANDERBILT UNIVERSITY   (United States)

^d VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS VACCINE;

ADULT; AGED; ARTICLE; EPIDEMIC; FEMALE; HEALTH CARE PERSONNEL; HUMAN; HUMORAL IMMUNITY; INFECTION CONTROL; MAJOR CLINICAL STUDY; MALE; PERTUSSIS; PRIORITY JOURNAL;

ADULT; AGED; ANTIBODIES, BACTERIAL; DIPHTHERIA-TETANUS-ACELLULAR PERTUSSIS VACCINES; DISEASE OUTBREAKS; FEMALE; HEALTH PERSONNEL; HUMANS; IMMUNIZATION, SECONDARY; MALE; MIDDLE AGED; WHOOPING COUGH; YOUNG ADULT;

EID: 67651177779     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/603555     Document Type: Article

References (11)

1. Baggett HC, Duchin JS, Shelton W, et al. Two nosocomial pertussis outbreaks and their associated costs-King County, Washington, 2004. Infect control Hosp Epidemiol 2007; 28:537-43.
2. Ward A, Caro J, Bassinet L, Housset B, O'Brien JA, Guiso N. Health and economic consequences of an outbreak of pertussis among healthcare workers in a hospital in France. Infect Control Hosp Epidemiol 2005; 26:288-92.
3. Calugar A, Ortega-Sanchez IR, Tiwari T, Oakes L, Jahre JA, Murphy TV. Nosocomial pertussis: costs of an outbreak and benefits of vaccinating health care workers. Clin Infect Dis 2006; 42:981-8.
4. Sandora TJ, Gidengil CA, Lee GM. Pertussis vaccination for health care workers. Clin Microbiol Rev 2008; 21:426-34.
5. Centers for Disease Control and Prevention. Preventing tetanus, diphtheria, and pertussis among adults: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP) and recommendation of ACIP, supported by the Healthcare Infection Control Practices Advisory Committee (HICPAC), for use of Tdap among health-care personnel. MMWR Recomm Rep 2006; 55(RR-17):1-37.
6. Food and Drug Administration. Vaccines and Related Biological Products Advisory Committee, March 15, 2005: FDA clinical briefing document for tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed (Tdap, ADACEL), Aventis Pasteur, Limited. Rockville, MD: US Department of Health and Human Services, Food and Drug Administration, 2005. Available at: http://www.fda.gov/ohrms/dockets/ac/05/briefing/2005-4097B1-4a.pdf. Accessed 26 June 2009.
7. Edwards KM, Decker MD. Pertussis Vaccine. In: Plotkin S, Orenstein WA, Offit P, eds. Vaccines, 5th ed. Philadelphia: WB Saunders, 2008: 467-518.
8. Storsaeter J, Hallander HO, Gustafsson L, Olin P. Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis. Vaccine 1998; 16:1907-16.
9. Davis JP. Clinical and economic effects of pertussis outbreaks. Pediatr Infect Dis J 2005;24:S109-16.
10. Zivna I, Bergin D, Casavant J, et al. Impact of Bordetella pertussis exposures on a Massachusetts tertiary care medical center. Infect Control Hosp Epidemiol 2007;28:708-12.
11. Centers for Disease Control and Prevention. Outbreaks of respiratory illness mistakenly attributed to pertussis-New Hampshire, Massachusetts, Tennessee, 2004-2006. MMWR Morb Mortal Wkly Rep 2007;56: 837-842.